Biotechnology specialist Ginkgo Bioworks (NYSE: DNA ) is seeing shares skyrocket today following an announcement of a potentially lucrative collaboration. Specifically, Ginkgo will partner with Syngenta , which is billed as a “leader in agricultural innovation.” Together, the two will work to launch a new biological solution.
Given the underlying credibility boost, DNA stock is up around 20% as of this writing. According to a press release , Ginkgo aims to “develop and optimize” a microbial strain for a secondary metabolite under Syngenta’s pipeline. On a scientific basis, Syngenta’s research team has identified the biological solution as a high-potential asset.
Financially, the partnership also offers a cost-effective approach toward large-scale production of the targeted metabolite. Primarily, the advantage that Ginkgo offers is its specialty in cell programming. Per the press release, Ginkgo may leverage its biological knowledge along with its machine-learning capabilities.
These attributes can help optimize the microbial strain to meet Syngenta’s productivity targets. The two enterprises did not specifically reveal the end purpose or application of the biological solution. However, one Syngenta representative noted that “biologicals are increasingly important in addressing the need for efficient and sustainable agricultural solutions worldwide.
’ DNA Stock Receives a Reputational Tailwind, But Challenges Linger Based on comments from Syngenta, the broader.